View ValuationZhejiang NHU 향후 성장Future 기준 점검 2/6Zhejiang NHU (는) 각각 연간 11.8% 및 7.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 20% 로 예상됩니다.핵심 정보11.8%이익 성장률9.46%EPS 성장률Chemicals 이익 성장30.0%매출 성장률7.9%향후 자기자본이익률20.04%애널리스트 커버리지Good마지막 업데이트26 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesDeclared Dividend • May 23Dividend of CN¥0.80 announcedShareholders will receive a dividend of CN¥0.80. Ex-date: 28th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 28% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Apr 16Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China공시 • Mar 31Zhejiang NHU Company Ltd. to Report Q1, 2026 Results on Apr 29, 2026Zhejiang NHU Company Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026공시 • Dec 31Zhejiang NHU Company Ltd. to Report Fiscal Year 2025 Results on Apr 16, 2026Zhejiang NHU Company Ltd. announced that they will report fiscal year 2025 results on Apr 16, 2026공시 • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2025 Results on Oct 29, 2025Zhejiang NHU Company Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025공시 • Sep 16Zhejiang Nhu Company Ltd. Approves Interim Dividend for 2025Zhejiang NHU Company Ltd. held its 2nd Extraordinary General Meeting of 2025 on 12 September 2025, approved interim Cash dividend/10 shares (tax included): CNY2.00000000 for 2025.공시 • Aug 29Zhejiang Nhu Company Ltd. Proposes Interim Cash Dividend for 2025Zhejiang NHU Company Ltd. proposed 2025 interim dividend at its EGM to be held on 12 September 2025, a Cash dividend (tax included) of CNY 2.00000000 per ten shares.공시 • Jul 02Zhejiang NHU Company Ltd. to Report First Half, 2025 Results on Aug 28, 2025Zhejiang NHU Company Ltd. announced that they will report first half, 2025 results on Aug 28, 2025공시 • Apr 16+ 1 more updateZhejiang NHU Company Ltd. (SZSE:002001) announces an Equity Buyback for $600 million worth of its shares.Zhejiang NHU Company Ltd. (SZSE:002001) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its shares. The price for the share repurchase will not exceed CNY 32 per share. The shares repurchased will be used for equity incentive or employee stock ownership plan. The program will be funded using the company's own funds or a dedicated repurchase loan. The program is valid for 12 months.공시 • Apr 15Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China공시 • Mar 31Zhejiang NHU Company Ltd. to Report Q1, 2025 Results on Apr 29, 2025Zhejiang NHU Company Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025공시 • Jan 16Zhejiang Nhu Company Ltd. Announces Special Dividend of the Year 2024 of A Shares, Payable on 22 January 2025Zhejiang NHU Company Ltd. announced special cash dividend/10 shares (tax included) of CNY 5.00000000 for year 2024 of A shares. Record date is 21 January 2025. Ex-date is 22 January 2025. Payment date is 22 January 2025.공시 • Dec 31Zhejiang NHU Company Ltd. to Report Fiscal Year 2024 Results on Apr 15, 2025Zhejiang NHU Company Ltd. announced that they will report fiscal year 2024 results on Apr 15, 2025공시 • Dec 20Zhejiang NHU Company Ltd. Proposes Special Cash Dividend for the Third Quarter of 2024Zhejiang NHU Company Ltd. proposed special cash dividend of CNY 2.00 per 10 shares for the third quarter of 2024.Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.20 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.58 (up from CN¥0.20 in 3Q 2023). Revenue: CN¥5.94b (up 65% from 3Q 2023). Net income: CN¥1.79b (up 189% from 3Q 2023). Profit margin: 30% (up from 17% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥22.57, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 9.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.71 per share.공시 • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2024 Results on Oct 24, 2024Zhejiang NHU Company Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.27 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.43 (up from CN¥0.27 in 2Q 2023). Revenue: CN¥5.35b (up 41% from 2Q 2023). Net income: CN¥1.33b (up 59% from 2Q 2023). Profit margin: 25% (up from 22% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.공시 • Jun 29Zhejiang NHU Company Ltd. to Report First Half, 2024 Results on Aug 23, 2024Zhejiang NHU Company Ltd. announced that they will report first half, 2024 results on Aug 23, 2024공시 • May 25Zhejiang NHU Company Ltd. Proposes Final Cash Dividend (A Shares) for the Year 2023, Payable on 29 May 2024Zhejiang NHU Company Ltd. Proposed final cash dividend (A shares) (tax included) of CNY 4.50000000 per ten shares for the year 2023. Record date: 28 May 2024, Ex-date: 29 May 2024, Payment date: 29 May 2024. Net cash dividend/10 shares after tax: CNY 4.05000000 (CNY 4.50000000- CNY 0.45000000).Reported Earnings • Apr 24Full year 2023 earnings released: EPS: CN¥0.88 (vs CN¥1.17 in FY 2022)Full year 2023 results: EPS: CN¥0.88 (down from CN¥1.17 in FY 2022). Revenue: CN¥15.1b (down 5.1% from FY 2022). Net income: CN¥2.70b (down 25% from FY 2022). Profit margin: 18% (down from 23% in FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.공시 • Apr 23Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China공시 • Mar 30Zhejiang NHU Company Ltd. to Report Q1, 2024 Results on Apr 30, 2024Zhejiang NHU Company Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024공시 • Dec 29Zhejiang NHU Company Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024Zhejiang NHU Company Ltd. announced that they will report fiscal year 2023 results on Apr 23, 2024Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.26 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.26 in 3Q 2022). Revenue: CN¥3.59b (down 2.7% from 3Q 2022). Net income: CN¥618.0m (down 23% from 3Q 2022). Profit margin: 17% (down from 22% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year.공시 • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2023 Results on Oct 27, 2023Zhejiang NHU Company Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023공시 • Sep 21Zhejiang NHU Company Ltd. Announces Executive AppointmentsZhejiang NHU Company Ltd. at the Extraordinary General Meeting of 2023 on 19 September 2023 approved election of non-independent directors, cumulative voting system applicable: Yu Hongwei; Election of independent directors, cumulative voting system applicable: Shen Yuping, Wan Feng, Wang Yang; Election of non-employee supervisors, cumulative voting system applicable: Zhao Jia and Wang Xiaobi.Reported Earnings • Aug 30Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.33 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.27 (down from CN¥0.33 in 2Q 2022). Revenue: CN¥3.81b (down 2.6% from 2Q 2022). Net income: CN¥840.1m (down 17% from 2Q 2022). Profit margin: 22% (down from 26% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.공시 • Jun 09Zhejiang NHU Company Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 14, 2023Zhejiang NHU Company Ltd. announced final cash dividend/10 shares (tax included) of CNY 5.00000000 on A shares for the year 2022. Record date is June 13, 2023. Ex-date is May June 14, 2023. Payment date is June 14, 2023.공시 • May 23Zhejiang NHU Company Ltd. Approves Cash Dividend for 2022Zhejiang NHU Company Ltd. at its Annual General Meeting of 2022 held on 19 May 2023, approved cash dividend/10 shares (tax included): CNY 5.00000000.Reported Earnings • Apr 21First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.39 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.39 in 1Q 2022). Revenue: CN¥3.61b (down 16% from 1Q 2022). Net income: CN¥643.2m (down 47% from 1Q 2022). Profit margin: 18% (down from 28% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 25Full year 2022 earnings released: EPS: CN¥1.18 (vs CN¥1.40 in FY 2021)Full year 2022 results: EPS: CN¥1.18 (down from CN¥1.40 in FY 2021). Revenue: CN¥15.9b (up 7.7% from FY 2021). Net income: CN¥3.64b (down 16% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.31 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.26 (down from CN¥0.31 in 3Q 2021). Revenue: CN¥3.69b (up 13% from 3Q 2021). Net income: CN¥797.2m (down 17% from 3Q 2021). Profit margin: 22% (down from 30% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥18.31, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.65 per share.Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.42 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.33 (down from CN¥0.42 in 2Q 2021). Revenue: CN¥3.91b (up 10% from 2Q 2021). Net income: CN¥1.01b (down 21% from 2Q 2021). Profit margin: 26% (down from 36% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.44 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.47 (up from CN¥0.44 in 1Q 2021). Revenue: CN¥4.31b (up 15% from 1Q 2021). Net income: CN¥1.20b (up 5.9% from 1Q 2021). Profit margin: 28% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.4%, compared to a 25% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 16Full year 2021 earnings released: EPS: CN¥1.68 (vs CN¥1.38 in FY 2020)Full year 2021 results: EPS: CN¥1.68 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 44% from FY 2020). Net income: CN¥4.32b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.6%, compared to a 28% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year.Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥1.67 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 43% from FY 2020). Net income: CN¥4.31b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 5.1%, compared to a 25% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.28 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥3.26b (up 50% from 3Q 2020). Net income: CN¥957.6m (up 32% from 3Q 2020). Profit margin: 29% (down from 34% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 20Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.51 in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥3.51b (up 31% from 2Q 2020). Net income: CN¥1.27b (down 2.8% from 2Q 2020). Profit margin: 36% (down from 49% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.42 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥3.74b (up 43% from 1Q 2020). Net income: CN¥1.14b (up 26% from 1Q 2020). Profit margin: 30% (down from 34% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥1.66 (vs CN¥1.01 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥10.3b (up 35% from FY 2019). Net income: CN¥3.56b (up 64% from FY 2019). Profit margin: 35% (up from 28% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Feb 20New 90-day high: CN¥42.75The company is up 28% from its price of CN¥33.31 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.02 per share.Is New 90 Day High Low • Jan 20New 90-day high: CN¥41.05The company is up 46% from its price of CN¥28.06 on 23 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.55 per share.Valuation Update With 7 Day Price Move • Jan 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥39.29, the stock is trading at a trailing P/E ratio of 24.7x, up from the previous P/E ratio of 21.2x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 64%.Is New 90 Day High Low • Dec 31New 90-day high: CN¥33.68The company is up 13% from its price of CN¥29.79 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.92 per share.Is New 90 Day High Low • Dec 09New 90-day high: CN¥33.40The company is up 6.0% from its price of CN¥31.46 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.70 per share.Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥3.40b, up 51% from the prior year. Total revenue was CN¥9.33b over the last 12 months, up 21% from the prior year.Analyst Estimate Surprise Post Earnings • Oct 29Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 31% at CN¥2.18b. Revenue is forecast to grow 45% over the next year, compared to a 30% growth forecast for the Pharmaceuticals industry in China.Is New 90 Day High Low • Oct 20New 90-day low: CN¥28.51The company is down 5.0% from its price of CN¥30.12 on 22 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥16.10 per share.이익 및 매출 성장 예측XSEC:002001 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202829,60110,1089,41112,121712/31/202727,8779,2188,44411,180912/31/202627,4499,4557,0118,33293/31/202623,1066,7126,9318,885N/A12/31/202522,2516,7646,8978,797N/A9/30/202522,4707,2006,1788,139N/A6/30/202522,8667,2686,7778,177N/A3/31/202522,5506,8796,8728,188N/A12/31/202421,6105,8695,4737,073N/A9/30/202419,8864,5934,8567,071N/A6/30/202417,5433,4253,1176,022N/A3/31/202416,0032,9311,3125,209N/A12/31/202315,1172,7046745,119N/A9/30/202315,0362,710-9024,459N/A6/30/202315,1372,890-1,1494,355N/A3/31/202315,2383,060-8654,330N/A1/1/202315,9343,620-5704,361N/A9/30/202216,2133,9753324,509N/A6/30/202215,7924,1438444,791N/A3/31/202215,4354,4151,5375,176N/A1/1/202214,9174,3562,3655,838N/A9/30/202113,4554,0201,9864,935N/A6/30/202112,3513,7821,6844,285N/A3/31/202111,4803,8081,4933,949N/A12/31/202010,3143,5647703,123N/A9/30/20209,3383,398-953,053N/A6/30/20209,0743,221-1,2482,479N/A3/31/20208,4492,554-2,1222,110N/A12/31/20197,6602,165N/A2,107N/A9/30/20197,7602,244N/A2,255N/A6/30/20197,9212,173N/A2,603N/A3/31/20197,4742,096N/A3,522N/A12/31/20188,6833,079N/A3,660N/A9/30/20188,8623,341N/A3,017N/A6/30/20188,2783,177N/A2,711N/A3/31/20188,0532,966N/A1,590N/A12/31/20176,2351,704N/A1,324N/A9/30/20175,3661,258N/A1,249N/A6/30/20175,0021,273N/A1,178N/A3/31/20174,8381,279N/A1,137N/A12/31/20164,6961,203N/A1,190N/A9/30/20164,414962N/A1,202N/A6/30/20164,194732N/A1,090N/A3/31/20163,951477N/A1,042N/A12/31/20153,823402N/A972N/A9/30/20153,965380N/A758N/A6/30/20153,965445N/A906N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 002001 의 연간 예상 수익 증가율(11.8%)이 saving rate(2.4%)보다 높습니다.수익 vs 시장: 002001 의 연간 수익(11.8%)이 CN 시장(26.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 002001 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 002001 의 수익(연간 7.9%)이 CN 시장(연간 16.3%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 002001 의 수익(연간 7.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 002001의 자본 수익률은 3년 후 20%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/13 17:54종가2026/06/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Zhejiang NHU Company Ltd.는 19명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Xiongwei JiaChina International Capital Corporation LimitedSophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)Zhe WangCitic Securities Co., Ltd.16명의 분석가 더 보기
Declared Dividend • May 23Dividend of CN¥0.80 announcedShareholders will receive a dividend of CN¥0.80. Ex-date: 28th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 28% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Apr 16Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China
공시 • Mar 31Zhejiang NHU Company Ltd. to Report Q1, 2026 Results on Apr 29, 2026Zhejiang NHU Company Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
공시 • Dec 31Zhejiang NHU Company Ltd. to Report Fiscal Year 2025 Results on Apr 16, 2026Zhejiang NHU Company Ltd. announced that they will report fiscal year 2025 results on Apr 16, 2026
공시 • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2025 Results on Oct 29, 2025Zhejiang NHU Company Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
공시 • Sep 16Zhejiang Nhu Company Ltd. Approves Interim Dividend for 2025Zhejiang NHU Company Ltd. held its 2nd Extraordinary General Meeting of 2025 on 12 September 2025, approved interim Cash dividend/10 shares (tax included): CNY2.00000000 for 2025.
공시 • Aug 29Zhejiang Nhu Company Ltd. Proposes Interim Cash Dividend for 2025Zhejiang NHU Company Ltd. proposed 2025 interim dividend at its EGM to be held on 12 September 2025, a Cash dividend (tax included) of CNY 2.00000000 per ten shares.
공시 • Jul 02Zhejiang NHU Company Ltd. to Report First Half, 2025 Results on Aug 28, 2025Zhejiang NHU Company Ltd. announced that they will report first half, 2025 results on Aug 28, 2025
공시 • Apr 16+ 1 more updateZhejiang NHU Company Ltd. (SZSE:002001) announces an Equity Buyback for $600 million worth of its shares.Zhejiang NHU Company Ltd. (SZSE:002001) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its shares. The price for the share repurchase will not exceed CNY 32 per share. The shares repurchased will be used for equity incentive or employee stock ownership plan. The program will be funded using the company's own funds or a dedicated repurchase loan. The program is valid for 12 months.
공시 • Apr 15Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025Zhejiang NHU Company Ltd., Annual General Meeting, May 08, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China
공시 • Mar 31Zhejiang NHU Company Ltd. to Report Q1, 2025 Results on Apr 29, 2025Zhejiang NHU Company Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
공시 • Jan 16Zhejiang Nhu Company Ltd. Announces Special Dividend of the Year 2024 of A Shares, Payable on 22 January 2025Zhejiang NHU Company Ltd. announced special cash dividend/10 shares (tax included) of CNY 5.00000000 for year 2024 of A shares. Record date is 21 January 2025. Ex-date is 22 January 2025. Payment date is 22 January 2025.
공시 • Dec 31Zhejiang NHU Company Ltd. to Report Fiscal Year 2024 Results on Apr 15, 2025Zhejiang NHU Company Ltd. announced that they will report fiscal year 2024 results on Apr 15, 2025
공시 • Dec 20Zhejiang NHU Company Ltd. Proposes Special Cash Dividend for the Third Quarter of 2024Zhejiang NHU Company Ltd. proposed special cash dividend of CNY 2.00 per 10 shares for the third quarter of 2024.
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.20 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.58 (up from CN¥0.20 in 3Q 2023). Revenue: CN¥5.94b (up 65% from 3Q 2023). Net income: CN¥1.79b (up 189% from 3Q 2023). Profit margin: 30% (up from 17% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥22.57, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 9.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.71 per share.
공시 • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2024 Results on Oct 24, 2024Zhejiang NHU Company Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.27 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.43 (up from CN¥0.27 in 2Q 2023). Revenue: CN¥5.35b (up 41% from 2Q 2023). Net income: CN¥1.33b (up 59% from 2Q 2023). Profit margin: 25% (up from 22% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
공시 • Jun 29Zhejiang NHU Company Ltd. to Report First Half, 2024 Results on Aug 23, 2024Zhejiang NHU Company Ltd. announced that they will report first half, 2024 results on Aug 23, 2024
공시 • May 25Zhejiang NHU Company Ltd. Proposes Final Cash Dividend (A Shares) for the Year 2023, Payable on 29 May 2024Zhejiang NHU Company Ltd. Proposed final cash dividend (A shares) (tax included) of CNY 4.50000000 per ten shares for the year 2023. Record date: 28 May 2024, Ex-date: 29 May 2024, Payment date: 29 May 2024. Net cash dividend/10 shares after tax: CNY 4.05000000 (CNY 4.50000000- CNY 0.45000000).
Reported Earnings • Apr 24Full year 2023 earnings released: EPS: CN¥0.88 (vs CN¥1.17 in FY 2022)Full year 2023 results: EPS: CN¥0.88 (down from CN¥1.17 in FY 2022). Revenue: CN¥15.1b (down 5.1% from FY 2022). Net income: CN¥2.70b (down 25% from FY 2022). Profit margin: 18% (down from 23% in FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.
공시 • Apr 23Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024Zhejiang NHU Company Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinchang County, Zhejiang China
공시 • Mar 30Zhejiang NHU Company Ltd. to Report Q1, 2024 Results on Apr 30, 2024Zhejiang NHU Company Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024
공시 • Dec 29Zhejiang NHU Company Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024Zhejiang NHU Company Ltd. announced that they will report fiscal year 2023 results on Apr 23, 2024
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.26 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.26 in 3Q 2022). Revenue: CN¥3.59b (down 2.7% from 3Q 2022). Net income: CN¥618.0m (down 23% from 3Q 2022). Profit margin: 17% (down from 22% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year.
공시 • Sep 30Zhejiang NHU Company Ltd. to Report Q3, 2023 Results on Oct 27, 2023Zhejiang NHU Company Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
공시 • Sep 21Zhejiang NHU Company Ltd. Announces Executive AppointmentsZhejiang NHU Company Ltd. at the Extraordinary General Meeting of 2023 on 19 September 2023 approved election of non-independent directors, cumulative voting system applicable: Yu Hongwei; Election of independent directors, cumulative voting system applicable: Shen Yuping, Wan Feng, Wang Yang; Election of non-employee supervisors, cumulative voting system applicable: Zhao Jia and Wang Xiaobi.
Reported Earnings • Aug 30Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.33 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.27 (down from CN¥0.33 in 2Q 2022). Revenue: CN¥3.81b (down 2.6% from 2Q 2022). Net income: CN¥840.1m (down 17% from 2Q 2022). Profit margin: 22% (down from 26% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.
공시 • Jun 09Zhejiang NHU Company Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 14, 2023Zhejiang NHU Company Ltd. announced final cash dividend/10 shares (tax included) of CNY 5.00000000 on A shares for the year 2022. Record date is June 13, 2023. Ex-date is May June 14, 2023. Payment date is June 14, 2023.
공시 • May 23Zhejiang NHU Company Ltd. Approves Cash Dividend for 2022Zhejiang NHU Company Ltd. at its Annual General Meeting of 2022 held on 19 May 2023, approved cash dividend/10 shares (tax included): CNY 5.00000000.
Reported Earnings • Apr 21First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.39 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.39 in 1Q 2022). Revenue: CN¥3.61b (down 16% from 1Q 2022). Net income: CN¥643.2m (down 47% from 1Q 2022). Profit margin: 18% (down from 28% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 25Full year 2022 earnings released: EPS: CN¥1.18 (vs CN¥1.40 in FY 2021)Full year 2022 results: EPS: CN¥1.18 (down from CN¥1.40 in FY 2021). Revenue: CN¥15.9b (up 7.7% from FY 2021). Net income: CN¥3.64b (down 16% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.31 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.26 (down from CN¥0.31 in 3Q 2021). Revenue: CN¥3.69b (up 13% from 3Q 2021). Net income: CN¥797.2m (down 17% from 3Q 2021). Profit margin: 22% (down from 30% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥18.31, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.65 per share.
Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.42 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.33 (down from CN¥0.42 in 2Q 2021). Revenue: CN¥3.91b (up 10% from 2Q 2021). Net income: CN¥1.01b (down 21% from 2Q 2021). Profit margin: 26% (down from 36% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.44 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.47 (up from CN¥0.44 in 1Q 2021). Revenue: CN¥4.31b (up 15% from 1Q 2021). Net income: CN¥1.20b (up 5.9% from 1Q 2021). Profit margin: 28% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.4%, compared to a 25% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 16Full year 2021 earnings released: EPS: CN¥1.68 (vs CN¥1.38 in FY 2020)Full year 2021 results: EPS: CN¥1.68 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 44% from FY 2020). Net income: CN¥4.32b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.6%, compared to a 28% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year.
Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥1.67 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.8b (up 43% from FY 2020). Net income: CN¥4.31b (up 21% from FY 2020). Profit margin: 29% (down from 35% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 5.1%, compared to a 25% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.28 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥3.26b (up 50% from 3Q 2020). Net income: CN¥957.6m (up 32% from 3Q 2020). Profit margin: 29% (down from 34% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 20Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.51 in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥3.51b (up 31% from 2Q 2020). Net income: CN¥1.27b (down 2.8% from 2Q 2020). Profit margin: 36% (down from 49% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.42 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥3.74b (up 43% from 1Q 2020). Net income: CN¥1.14b (up 26% from 1Q 2020). Profit margin: 30% (down from 34% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥1.66 (vs CN¥1.01 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥10.3b (up 35% from FY 2019). Net income: CN¥3.56b (up 64% from FY 2019). Profit margin: 35% (up from 28% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Feb 20New 90-day high: CN¥42.75The company is up 28% from its price of CN¥33.31 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.02 per share.
Is New 90 Day High Low • Jan 20New 90-day high: CN¥41.05The company is up 46% from its price of CN¥28.06 on 23 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.55 per share.
Valuation Update With 7 Day Price Move • Jan 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥39.29, the stock is trading at a trailing P/E ratio of 24.7x, up from the previous P/E ratio of 21.2x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 64%.
Is New 90 Day High Low • Dec 31New 90-day high: CN¥33.68The company is up 13% from its price of CN¥29.79 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.92 per share.
Is New 90 Day High Low • Dec 09New 90-day high: CN¥33.40The company is up 6.0% from its price of CN¥31.46 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.70 per share.
Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥3.40b, up 51% from the prior year. Total revenue was CN¥9.33b over the last 12 months, up 21% from the prior year.
Analyst Estimate Surprise Post Earnings • Oct 29Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 31% at CN¥2.18b. Revenue is forecast to grow 45% over the next year, compared to a 30% growth forecast for the Pharmaceuticals industry in China.
Is New 90 Day High Low • Oct 20New 90-day low: CN¥28.51The company is down 5.0% from its price of CN¥30.12 on 22 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥16.10 per share.